-
Founded in:
1994-06-08 -
Country:
China -
Address:
No. 15, Chuangye Road, High-tech Zone, Yantai City, Shandong Province -
Tax NO.:
913706001650849788 -
Registered Funds:
2,031.8 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| An enzyme that activates plasminogen, extracted from fresh human urine |
This product directly acts on the endogenous fibrinolytic system, catalyzing the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis.
More
This product directly acts on the endogenous fibrinolytic system, catalyzing the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pantoprazole Sodium |
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After continuous use of pantoprazole at a dose of 40 to 80 mg/d for 2.5 years, there was no change in various experimental parameters of liver enzymology and cholesterol metabolism.
More
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After continuous use of pantoprazole at a dose of 40 to 80 mg/d for 2.5 years, there was no change in various experimental parameters of liver enzymology and cholesterol metabolism. |
138786-67-1 | 57 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pantoprazole Sodium |
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After continuous use of pantoprazole at a dose of 40 to 80 mg/d for 2.5 years, there was no change in various experimental parameters of liver enzymology and cholesterol metabolism.
More
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After continuous use of pantoprazole at a dose of 40 to 80 mg/d for 2.5 years, there was no change in various experimental parameters of liver enzymology and cholesterol metabolism. |
138786-67-1 | 57 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pantoprazole Sodium |
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After 2.5 years of continuous medication, there were no changes in various experimental parameters of liver enzymology and cholesterol metabolism.
More
This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After 2.5 years of continuous medication, there were no changes in various experimental parameters of liver enzymology and cholesterol metabolism. |
138786-67-1 | 57 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Glutathione |
Reduced glutathione (GSH) is a peptide naturally synthesized in human cytoplasm. It is composed of glutamic acid, cysteine and glycine, contains sulfhydryl (-SH) and is widely distributed in various organs of the body. It has played an important role in maintaining the biological functions of cells. It is the cofactor of glyceraldehyde phosphate dehydrogenase, and the coenzyme of glyoxalase and triose dehydrogenase. It participates in the tricarboxylic acid cycle and sugar metabolism in the body. This product can activate a variety of enzymes [such as sulfhydryl (-SH) enzymes, etc.], thereby promoting the metabolism of sugar, fat and protein, and can affect the metabolic process of cells; it can combine with free radicals in the body through sulfhydryl groups, and can be converted into easily metabolized acids to accelerate the excretion of free radicals, which helps to reduce the toxic side effects of chemotherapy and radiotherapy, and has no obvious effect on the efficacy of chemotherapy and radiotherapy. For example, the main mechanism for protecting renal tubules from damage by cisplatin is that the renal tubular cells contain r-glutamyl aminotransferase required for glutathione detoxification, but the renal cells do not have this enzyme, so it does not affect the cytotoxic effect of this product while protecting normal tissues and organs. It is also effective in treating radiation enteritis; it can reduce tissue damage and promote repair in patients with systemic or local hypoxemia caused by anemia, poisoning or tissue inflammation. Through transmethylation and transpropylamination reactions, GSH can also protect the liver's synthesis, detoxification, and hormone inactivation functions, and promote bile acid metabolism, which is beneficial to the absorption of fat and fat-soluble vitamins (A, D, E, K) in the digestive tract.
More
Reduced glutathione (GSH) is a peptide naturally synthesized in human cytoplasm. It is composed of glutamic acid, cysteine and glycine, contains sulfhydryl (-SH) and is widely distributed in various organs of the body. It has played an important role in maintaining the biological functions of cells. It is the cofactor of glyceraldehyde phosphate dehydrogenase, and the coenzyme of glyoxalase and triose dehydrogenase. It participates in the tricarboxylic acid cycle and sugar metabolism in the body. This product can activate a variety of enzymes [such as sulfhydryl (-SH) enzymes, etc.], thereby promoting the metabolism of sugar, fat and protein, and can affect the metabolic process of cells; it can combine with free radicals in the body through sulfhydryl groups, and can be converted into easily metabolized acids to accelerate the excretion of free radicals, which helps to reduce the toxic side effects of chemotherapy and radiotherapy, and has no obvious effect on the efficacy of chemotherapy and radiotherapy. For example, the main mechanism for protecting renal tubules from damage by cisplatin is that the renal tubular cells contain r-glutamyl aminotransferase required for glutathione detoxification, but the renal cells do not have this enzyme, so it does not affect the cytotoxic effect of this product while protecting normal tissues and organs. It is also effective in treating radiation enteritis; it can reduce tissue damage and promote repair in patients with systemic or local hypoxemia caused by anemia, poisoning or tissue inflammation. Through transmethylation and transpropylamination reactions, GSH can also protect the liver's synthesis, detoxification, and hormone inactivation functions, and promote bile acid metabolism, which is beneficial to the absorption of fat and fat-soluble vitamins (A, D, E, K) in the digestive tract. |
70-18-8 | 12 |